Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Wed7,675.70−0.02%

Nasdaq · Wed26,130.20−0.08%

Dow · Wed53,463.88−0.21%

Russell 2000 · Wed3,005.90−0.14%

VIX · Wed15.21unchanged

U.S. futures · 08:21ES +0.29%NQ +0.51% · YM +0.22%

U.S. 2Y / 10Y · 08:314.218% / 4.652%−0.6 / −1.2 bp vs prior close

Dollar index99.145−0.02%

WTI Oct / Gold Dec$81.36 / $4,663.70−1.06% / +0.22%

Nikkei / Hang Seng66,105 / 25,552−0.24% / −0.39%

Shanghai3,942.81+0.77%

Europe · Wed closeSTOXX 600 656.41FTSE 10,878 · DAX 26,286

1 · AI demand

NVIDIA validates acceleration

Fiscal Q2 revenue was $96.2B (+106% y/y), Data Center $89.0B (+117%), and non-GAAP EPS $2.22. Q3 revenue guidance is $108B ±2%, excluding China Data Center compute. NVIDIA release

2 · Market reaction

Futures confirm only the first step

NQ futures +0.51% and ES +0.29% are constructive, but neither is a regular-session close and Nasdaq premarket stock prints were unavailable before 04:00 ET. Avoid inferring NVDA's cash open from futures alone. CNBC NQ

3 · Geopolitics

Hormuz tail risk remains asymmetric

CNBC's 05:29 UTC report says a tanker attack is testing claims that the strait is functioning. WTI is nevertheless −1.06%, so price and headline risk diverge; a confirmed shipping disruption could reverse oil abruptly. CNBC

Market drivers

Macro, rates and geopolitics

Wednesday was consolidation, not capitulation: all four U.S. cash indices slipped 0.02%–0.21% and VIX held 15.21. Overnight futures improve the tone but must hold through the U.S. open. S&P · Cboe VIX
Discount-rate pressure persists: 2Y 4.218% and 10Y 4.652% leave a +43 bp curve. Small overnight yield declines help duration, but 4.65% long rates still demand earnings delivery. 10Y · 2Y
Fed: the latest official monetary release remains Aug. 25 discount-rate minutes; the next scheduled FOMC/SEP is Sep. 15–16. Fed release · calendar
Oil signal is fragile: WTI's −1.06% move discounts immediate disruption even as tanker-attack reporting raises the probability of a shipping shock. Treat energy-sensitive positions as headline-exposed. WTI

Earnings, regulation and rotation

NVIDIA fundamentals: revenue +18% q/q, GAAP gross margin 75.0%, and Data Center +18% q/q. The Q3 guide excludes China Data Center compute, making export access upside optionality but also a material policy risk. primary release
Cross-check: NVIDIA's Aug. 26 10-Q XBRL reports $96.221B quarterly revenue, $72.142B gross profit and $59.688B net income, matching the release. SEC 10-Q
AI read-through already appeared in cash: ANET +5.92%, VRT +3.15%, MRVL +1.97%, while NVDA itself fell 1.59% before results. This is selective infrastructure leadership, not broad risk-on proof. ANET · VRT
Tonight: Marvell reports after the U.S. close; Nasdaq's eight-estimate EPS forecast is $0.65 and is vendor consensus, not company guidance. Its custom-silicon/networking outlook is the next confirmation point. Nasdaq calendar

Theme dashboards

AI · constructive

Compute acceleration; selectivity still required

Leaders: ANET +5.92%, VRT +3.15%, MRVL +1.97%. NVIDIA's $108B guide and full-production Vera Rubin commentary support compute, networking, power and cooling demand.
Laggards: NVDA −1.59% and AVGO −0.32% in Wednesday cash. The post-result reaction was not available at cutoff; futures cannot substitute for stock-specific price discovery.
Risk: valuation, 4.65% 10Y, China/export policy, customer concentration, interconnect/power constraints, financing structures and expectation saturation.

Quantum · highly speculative

Renewed risk-off and management transition

Laggards: QBTS −9.51%, RGTI −5.90%, IONQ −4.80%, QUBT −1.30%. This reverses Tuesday's partial bounce and materially underperforms Nasdaq −0.08%.
Primary filing: D-Wave's Aug. 25 8-K says CFO John Markovich retires Sep. 2 and Greg Golkov becomes acting CFO; the company says no disagreement caused the departure. SEC 8-K
Risk: commercialization, architecture, high valuation, cash burn/dilution and squeeze risk. No borrow availability or fee is asserted.

Peptide biotech

Weak large-cap tape; VKTX diverges

Wednesday: LLY −3.59%, NVO −3.02%, while small-cap VKTX gained 0.61%. One-day relative strength is insufficient to offset VKTX's clinical and financing risk.
Retatrutide evidence: TRIUMPH-2 is a completed randomized, double-blind Phase 3 trial with 1,152 participants. Primary outcomes are percent body-weight change and AHI change in a subset at week 80; the registry posts no results or statistics. NCT05929079
Risk: efficacy, GI/other safety, discontinuation, manufacturing, reimbursement, competition and label scope. VKTX's July S-3ASR permits financing but does not prove issuance. SEC

Ranked ideas — conditional; fewer is better

1Conditional bullish

ANET · Arista Networks (NYSE)

Risk class: large-cap, high-valuation AI networking · Classification: relative-strength long on confirmation · Applicable horizons: day trade and 1–4 week swing; 3–12+ months only with durable revenue/FCF delivery. Direction remains uncertain.

Thesis/catalyst: ANET closed $202.25 (+5.92%) on 7.66M shares, decisively clearing yesterday's $193.15 trigger before NVIDIA validated accelerating Data Center demand. Networking read-through is positive.

Evidence / counterargument: Nasdaq timestamps the move Aug. 26; NVIDIA says Spectrum-6 systems are arriving across AI factories. Counter: ANET moved before the print, so favorable expectations may be embedded; customer concentration, competition, valuation and rates remain risks.

Entry/confirmation: avoid chasing an opening gap; require a controlled hold above $200 and relative strength versus NQ, or a post-gap base. Invalidation/downside: close below $197, then $193.15; event-driven gaps can exceed levels. Nasdaq · NVIDIA

Thesis Confidence 78

Risk 82

Opportunity 72

2Conditional bullish

VRT · Vertiv (NYSE)

Risk class: large-cap/high-beta AI power and cooling · Classification: demand read-through long only after price confirmation · Applicable horizons: day trade and 1–4 week swing; 3–12+ months on backlog, margin and cash-flow evidence. Direction uncertain.

Thesis/catalyst: VRT gained 3.15% to $263.81 on 3.93M shares, reclaiming the prior report's $260 threshold. NVIDIA's guide supports AI-factory buildout and Vera Rubin deployment, which require power and thermal infrastructure.

Evidence / counterargument: Nasdaq verifies price/volume; NVIDIA names multiple cloud deployments. Counter: NVIDIA demand does not map one-for-one to VRT orders, and project timing, customer budgets, valuation, execution and yields can break the read-through.

Entry/confirmation: require $260–264 to hold after the U.S. open and positive data-center breadth; better entry is a base, not a vertical gap. Invalidation/downside: close below $255; broader failure below $250. Nasdaq

Thesis Confidence 72

Risk 85

Opportunity 66

1Avoid / bearish on failed bounce

QBTS · D-Wave Quantum (NYSE)

Risk class: small/high-beta speculative quantum; squeeze and dilution prone · Classification: avoid chase; bearish only on failed rebound · Applicable horizons: day trade; 1–4 week avoid/observe; no core 3–12+ month entry absent commercial de-risking. Direction uncertain.

Thesis/catalyst: QBTS fell 9.51% to $17.51 on 26.53M shares, more than reversing Tuesday's 3.59% bounce. The Sep. 2 CFO/acting-CFO transition adds execution monitoring.

Evidence / counterargument: Nasdaq verifies the close and volume; the SEC 8-K verifies the transition and says it was not due to disagreement. Counter: contracts, technical milestones, an orderly transition or renewed risk appetite can trigger a violent rebound.

Entry/confirmation: no blind short; bearish confirmation is a failed reclaim of $18 followed by a break below $17.50. Invalidation/downside: bearish view invalid above $18.68, then $19.35. Short losses are unlimited; availability/fees unknown. Nasdaq · SEC

Thesis Confidence 76

Risk 98

Opportunity 54

2Avoid opening chase

NVDA · NVIDIA (Nasdaq)

Risk class: mega-cap post-earnings gap/high expectations · Classification: avoid a vertical opening chase, not an outright short · Applicable horizons: day trade after price discovery; 1–4 week after a base; 3–12+ months tied to growth, margins and valuation. Direction uncertain.

Thesis/catalyst: the report is fundamentally strong, but NVDA fell 1.59% to $209.66 before results and NQ futures provide no stock-specific price. First reaction can reverse as investors assess the $108B guide, 74% margin guide and China exclusion.

Evidence / counterargument: release and SEC data validate extraordinary growth. Counter to avoidance: a clean hold above prior close $209.66/$213.05 and broad semiconductor confirmation could begin a sustained re-rating.

Entry/confirmation: wait 30–60 minutes; bullish confirmation requires a post-gap base and reclaim/hold above $213.05. Invalidation: avoidance expires after orderly price discovery; a break below $205/$200 worsens near-term structure. No short is recommended. Nasdaq · SEC

Thesis Confidence 92

Risk 94

Opportunity 48

No third bullish or bearish idea: overnight futures are encouraging, but stock-level premarket price discovery had not begun and Hormuz/rate risks argue against filling quotas.

Watchlist — maximum five

Ticker / risk class	Classification & horizon	Thesis / catalyst / counterargument	Confirmation / invalidation / risks	C / R / O
Watch MRVL Nasdaq · high-beta custom silicon/networking	Earnings reaction; day/swing after results, long term after guidance.	+1.97% to $245.11; reports tonight after NVDA's strong guide. Counter: event gap, concentration and expectations.	No pre-event swing chase. Post-results hold above $245/$250; failure below $240 weakens. Event risk dominates.	77 / 96 / 62
Watch AVGO Nasdaq · mega-cap custom silicon/networking	Read-through; day/swing, 3–12 months after Sep. 2 earnings.	−0.32% to $355.59 before NVDA. Counter: custom-silicon demand and VMware cash flow can restore leadership.	Reclaim $360/$363; invalidate below $350. Customer concentration, leverage, rates, event gap.	69 / 83 / 61
Watch CRM NYSE · large-cap enterprise cloud	Post-earnings reaction; day/swing after confirmed open.	CNBC reports shares jumped 12% after AI growth and an Anthropic investment gain. Counter: investment gains are not recurring operating AI revenue.	Require gap hold and guidance-backed breadth; no level before live premarket. Valuation, execution, headline reversal.	65 / 88 / 58
Watch IONQ / RGTI NYSE/Nasdaq · speculative quantum	Oversold watch, not buy; day only, 1–4 week observe.	−4.80%/−5.90% with broad theme weakness. Counter: high-beta rebounds can be abrupt.	Require reclaim of $40.03/$15.94 with volume; new lows invalidate. Cash burn, dilution, commercialization, squeeze.	70 / 97 / 42
Watch VKTX / NVO / LLY Nasdaq/NYSE · small-cap biotech / large pharma	Peptide divergence; swing only after confirmation; long term on clinical evidence.	VKTX +0.61% while NVO −3.02% and LLY −3.59%. No TRIUMPH-2 results are posted. Counter: one-day relative strength is weak evidence.	VKTX hold $34/reclaim $35; invalidate below $33. Trial, safety, cash runway/dilution, reimbursement, manufacturing.	64 / 92 / 53

C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, not outcome probability.

Changes versus the 2026-08-26 report

Regime improves from neutral/event-risk to conditional risk-on: NQ futures +0.51%, ES +0.29%, slightly lower yields and NVIDIA's strong guide improve the setup, but cash confirmation is absent.
ANET fully cleared yesterday's technical trigger: it closed $202.25, above both $190 and $193.15. It becomes the top conditional long, with a no-chase rule because the one-day move was +5.92%.
VRT also confirms its prior reclaim: $263.81 closes above $260 and NVIDIA supports the demand narrative; a $255 close now invalidates the tactical setup.
NVDA changes from pre-earnings avoidance to post-report price-discovery avoidance: fundamentals are now known and strong; the unknown is whether price can digest elevated expectations and the China exclusion.
Quantum deterioration validates caution: QBTS −9.51%, RGTI −5.90% and IONQ −4.80% reverse Tuesday's bounce; QBTS remains the clearest avoid/failed-bounce candidate.
Prior NVO bullish setup failed: NVO fell 3.02% to $47.19, below the $47.50 invalidation. It is removed from ranked bullish ideas rather than rationalized after the fact.

Important catalysts: next 7–30 days

Aug. 27 · U.S. open — NVIDIA and Salesforce price discovery
Stock-specific premarket had not opened at cutoff. NVIDIA's $108B guide and Salesforce's reported post-results jump can move semis/cloud broadly. NVIDIA · CNBC CRM

Aug. 27 · after U.S. close — Marvell
Custom silicon and networking confirmation after NVIDIA; consensus is not guidance. Nasdaq

Sep. 2 · D-Wave CFO transition / Broadcom expected earnings
QBTS acting-CFO transition becomes effective; AVGO is the next major AI infrastructure reset. QBTS SEC · AVGO

Sep. 3 · 14:30 CEST — U.S. trade balance
Official BEA release; tariff effects and revisions can move dollar, rates and cyclicals. BEA schedule

Sep. 15–16 · FOMC + projections
Statement, SEP and press conference can reprice yields and long-duration themes. Federal Reserve

Pipeline watch · date unconfirmed
TRIUMPH-2 is completed, but ClinicalTrials.gov contains no results. Do not assign a Lilly readout date until the company or registry does. Registry

Bottom line by horizon

Day trade

Bias: conditional risk-on after price discovery. Prefer ANET/VRT on controlled holds; do not chase NVDA's first print.

Biggest risk: opening-gap reversal or Hormuz headline. Invalidation: NQ futures losing 29,400 and cash semiconductors failing broad confirmation.

1–4 week swing

Bias: constructive AI infrastructure, but wait for bases after NVDA and MRVL. ANET above $197 and VRT above $255 are the best conditional structures.

Biggest risk: expectations/rates overwhelm earnings. Invalidation: S&P closes below 7,650 and NQ loses the overnight breakout while 10Y rises.

3–12+ month investment

Bias: favor profitable, cash-generative AI infrastructure; require commercial economics for quantum and clinical/regulatory evidence for peptide biotech.

Biggest risk: peak capex and policy/geopolitical shock. Invalidation: thesis improves with sustained FCF growth and lower yields; worsens if orders, margins or China access deteriorate.

Data quality & methodology

Timestamp/session: generated Thursday 08:33:20 CEST. CNBC direct exchange quote API was observed 08:20–08:31 CEST. U.S. cash indices and Nasdaq stock data are Aug. 26 closes; futures/rates/FX/commodities are overnight. Asian quotes were late-session. Europe and Nasdaq premarket had not opened at the nominal cutoff.
Successful live retrievals: CNBC direct market API and RSS; Nasdaq quote, summary, extended-trading and earnings APIs; NVIDIA Newsroom release/RSS; SEC submissions, filing index and XBRL company facts; Fed feed/calendar; BEA schedule page; ClinicalTrials.gov API. Research used well over five meaningful retrieval calls across market data, current news and primary sources.
Cross-check: SEC XBRL independently matches NVIDIA's $96.221B revenue, $72.142B gross profit and $59.688B net income. Nasdaq timestamps stock closes Aug. 26. CNBC's bulk stock cache incorrectly labels Aug. 26 values as Aug. 25, so Nasdaq is authoritative for stock dates; CNBC is used for broad indices/futures.
Blocked/limited sources: Yahoo chart API returned HTTP 429; generic search and extraction failed for insufficient service credits; NVIDIA Investor Relations returned HTTP 403; several guessed CNBC URLs returned 404. Alternatives succeeded via CNBC's direct API/RSS, Nasdaq, NVIDIA Newsroom and SEC. Russell futures were unavailable from the CNBC symbol queried, but Russell cash is available; no false Russell-futures value is supplied.
Current-news limitation: CNBC RSS provided timestamped headlines; inaccessible article markup limits detail, so the tanker item is described narrowly and not treated as official confirmation. Material corporate numbers rely on company/SEC primary sources.
Scoring: Confidence is evidence quality, never guaranteed probability. Risk rises with event gaps, valuation, liquidity, leverage, dilution, management transition and binary exposure. Opportunity balances asymmetry, evidence and timing. Levels are paper-tracking references, not orders.

Sources

Research disclaimer: Research and paper-tracking only—not individualized, guaranteed, fiduciary, legal or medical advice. Initial two weeks are paper-tracking. Prices can gap beyond invalidation levels; shorts can lose more than invested. Verify quotes, liquidity, taxes and suitability independently.